Welcome to 4DMedical, a global leader in advanced respiratory imaging solutions. At TSANZSRS 2026, we are proud to showcase our innovative software technologies that deliver detailed insights into lung function, supporting respiratory specialists in the diagnosis and monitoring of pulmonary disease with greater precision.
Our solutions integrate seamlessly with existing imaging workflows, providing enhanced visualisation and quantification of airflow and lung dynamics — all without the need for contrast agents. By partnering with 4DMedical, clinicians can access cutting-edge tools designed to support informed decision-making, improve efficiency, and help deliver the highest standard of patient care.
View the entire 4DMedical portfolio.
10-minute Lung Health Analysis Software Demonstrations
Join us for a live demonstration of our lung health analysis software and see how it can deliver new, actionable insights into respiratory function. Our solutions are designed to enhance diagnostic confidence, support clinical decision-making, and help improve patient care.
This oral and poster presentation describes a novel contrast-free CT method that uses paired inspiratory–expiratory scans to generate regional ventilation–perfusion maps and quantify V/Q mismatch in COPD. In 3,162 subjects from the COPDGene database, greater V/Q mismatch was associated with more severe GOLD stage and lower DLCO, suggesting the technique may help localise functional abnormalities linked to impaired gas exchange.
Presenter: Dr Kris Nilsen
This presentation describes a pilot study in patients with idiopathic pulmonary fibrosis showing that X-ray Velocimetry imaging can provide regional, dynamic measures of lung ventilation beyond the global assessment offered by standard pulmonary function tests. Several XV metrics correlated strongly with conventional lung function, and lower XV-derived tidal volume in patients with more advanced disease suggests potential value for functional assessment and disease stratification.
Presenter: Ms My My Tran
This presentation will examine how advanced imaging techniques can be used to identify mucus obstruction and map ventilation heterogeneity in chronic airways disease, with potential implications for more targeted assessment and management. The session will highlight the clinical utility of imaging in understanding complex airway dysfunction.
Presenter: Dr Nicole Reyne
This presentation reports a prospective study showing that advanced inspiratory–expiratory CT imaging, combining fissure-region ventilation and emphysema analysis, can predict collateral ventilation with high accuracy in patients being assessed for bronchoscopic lung volume reduction. Using Chartis as the reference standard, the model achieved strong diagnostic performance and suggests a promising, less invasive approach to pre-procedure planning.
Presenter: Dr Kris Nilsen
Saturday, 28 March | ANZSRS Session 3:30–5:00 | 3:30–3:45 River View 5
This oral and poster presentation reports that CT:VQ showed strong lobar-level correlations with SPECT for both ventilation (r=0.842) and perfusion (r=0.872) in 77 adults undergoing regional lung function assessment. The study also found that CT:VQ heterogeneity metrics correlated with FEV1/FVC and DLCO, supporting its potential as a fast, non-contrast alternative to SPECT.
Presenter: Dr Nina Eikelis
ORAL PRESENTATION Sunday, 29 March | TSANZ Session 10:30–12:00 | 11:00–11:15 Meeting Room 1
POSTER Sunday, 29 March | ANZSRS Session 3:15–4:45 | Exhibition Hall
In this pilot study of patients with idiopathic pulmonary fibrosis, X-ray Velocimetry imaging produced regional ventilation metrics that correlated strongly with standard pulmonary function measures, particularly FEV1 and FVC. The results suggest XV may offer additional physiological insight beyond global PFT measures and could help distinguish milder from more advanced disease.
Presenter: Ms My My Tran
Monday, 30 March | TSANZ Session 8:30–10:00 | 9:45–10:00 Meeting Room 2
This poster reports that CT LVAS was a feasible method for assessing ventilation inhomogeneity in children with early cystic fibrosis lung disease, with successful analysis in 76% of cases. Mean specific ventilation showed the strongest utility, being lower in children with abnormal air trapping and lung clearance index, and correlating moderately to strongly with air trapping on CT.
Presenter: Ms Rebecca Heyman (University of Queensland)
Poster: Sunday, 29 March | 4:45–6:15 Exhibition Hall
This poster reports prospective findings showing that CT:VQ can generate clinically interpretable 3D perfusion images from non-contrast inspiratory and expiratory CT scans, with strong agreement to SPECT across 77 subjects reviewed by six experienced radiologists. The high inter-modality agreement supports CT:VQ as a viable non-nuclear alternative for regional lung perfusion assessment across a range of clinical conditions.
Presenter: Dr Nina Eikelis
Poster: Sunday, 29 March | 4:15–6:15 Exhibition Hall
This poster provides an update on efforts to integrate paediatric X-ray Velocimetry into respiratory care, with early studies showing regional ventilation abnormalities in children with cystic fibrosis and primary ciliary dyskinesia that were not identified by traditional pulmonary function tests. It also outlines plans to expand XV imaging across multiple centres and disease groups, including asthma, supporting earlier diagnosis and more detailed tracking of where lung function changes occur in children.
Presenter: Associate Professor Martin Donnelley
Poster: Sunday, 29 March | 4:45–6:15 Exhibition Hall
This poster reports a feasibility study in 35 adults with chronic respiratory diseases showing that the novel XV scanner can successfully assess regional lung function. XV-derived metrics correlated with established measures including FEV1/FVC and LCI2.5, and ventilation maps identified regional areas of reduced ventilation not captured by standard lung function tests.
Presenter: Dr Megan Frohlich
Poster: Sunday, 29 March | 4:45–6:15 Exhibition Hall
This poster describes the use of CT LVAS in over 50 patients with unexplained dyspnoea or chronic cough, showing how the technology can provide functional insight when symptoms are not fully explained by standard pulmonary function tests or structural CT. In a real-world respiratory clinic, CT LVAS helped identify regional ventilation abnormalities and clarify mismatches between symptoms, PFTs and CT findings, informing subsequent clinical management.
Presenter: Paul Hamor
Poster: Sunday, 29 March | 4:45–6:15 Exhibition Hall
CT LVAS: “More accessible functional lung imaging: non-contrast CT-ventilation demonstrates strong association and agreement with PET ventilation”
AComputed Tomography (CT) ventilation imaging (CTVI) is an emerging ventilation imaging technique. CTVI implementations have been widely validated against alternative ventilation imaging techniques but have been limited to clinical research only. The first CTVI commercial product, CT LVAS (4DMedical, Melbourne, Australia), was recently released enabling its use in clinical practice. This study quantitatively compares ventilation images from CT LVAS and previously validated research CTVI algorithms to Galligas PET ventilation.
American Journal of Respiratory and Critical Care Medicine: “Temporal Exploration of COPD Phenotypes: Insights from the COPDGene and SPIROMICS Cohorts”
A longitudinal analysis over five years showed that nearly 30% of patients experienced changes in their disease phenotypes, with a general trend of progression from subclinical disease toward emphysema. These findings inform personalized treatment approaches and improve clinical trials to slow disease progression.
Population Health Screening—Identifying and Re-engaging At-risk Patients
Emphysema and COPD are underdiagnosed in up to 50% of patients, and often not identified until advanced stages. For these patients, options like Bronchoscopic Lung Volume Reduction (BLVR) or Lung Volume Reduction Surgery (LVRS) can have a significantly positive impact on a patient’s quality of life.
B4 Symptoms, in collaboration with Lahey Hospital and Medical Center, a B4-sponsored pilot site, initiated a comprehensive screening program using 4DMedical’s advanced imaging analysis software, based on Imbio Technology. This program aims to identify patients who could benefit from BLVR and LVRS therapies for advanced emphysema.
